

Nexsen Appoints Global Clinical Leader to the Board

International surgeon-scientist Professor Shekhar Kumta joins the Board as Non-Executive Director, bringing internationally recognised clinical expertise across Hong Kong, Australia, India and NHS-linked UK networks. His appointment enhances Nexsen's access to major health systems and strengthens the Company's regulatory and clinical adoption pathways as it advances the GBS Rapid point-of-care sensor and the broader rapid diagnostics platform towards Nexsen's international market-entry strategy in 2H 2026.

Investor Highlights:

- Globally renowned clinical leader with more than 45 years in senior medical roles joins board**
 Professor Kumta brings internationally recognised leadership from major institutions including the Chinese University of Hong Kong, Prince of Wales Hospital and The Northern Hospital
- Unlocks direct access to long-standing networks across major health systems**
 Strong relationships with clinicians, hospital group and research groups throughout Hong Kong, India and NHS-linked networks in the United Kingdom create immediate entry points for early evaluation and commercial discussions
- Strengthens execution across Nexsen's suite of rapid point-of-care diagnostics**
 Brings extensive clinical insight directly supporting Nexsen's GBS Rapid Sensor and expanding Kidney Function Diagnostics suite targeting the multi-hundred-million patient CKD and AKI markets
- Adds weight to global regulatory and market-entry pathways**
 Senior clinical leadership standing enhances Nexsen's engagement with regulators and health technology assessors across the United States, United Kingdom, Europe and Asia
- Accelerates access to high-quality clinical partnerships and clinical adoption**
 His international profile elevates Nexsen's ability to secure reputable trial sites and frontline adopters as the Company progresses toward its anticipated market-entry in 2H CY26

Nexsen Limited (ASX:NXX) (Nexsen or the Company), is pleased to announce the appointment of Professor Shekhar Kumta as Non-Executive Director, effective today.

Professor Kumta is a globally respected clinical leader, surgeon-scientist, and academic with more than 45 years of experience across Australia and Hong Kong. He has held senior faculty, hospital governance, and medical leadership roles, including positions at the Chinese University of Hong Kong, Prince of Wales Hospital, and The Northern Hospital, Victoria.

His appointment to the Board significantly enhances Nexsen's clinical, regulatory and commercial capability at a pivotal time in the development as it advances the GBS Rapid Sensor through clinical validation and prepares its Kidney Function Diagnostics platform for global regulatory engagement.

Professor Kumta's appointment supports Nexsen's transition from a development-stage company toward commercial readiness, and aligns with the Company's pathway toward FDA 510(k) submission and international market-entry from 2H CY2026.

This strengthened clinical leadership will support Nexsen's strategy to accelerate adoption of its point-of-care technologies in maternal health and renal medicine across key markets.

Professor Shekhar Kumta, Non-Executive Director, commented:

"Having worked across global health systems for nearly 5 decades, I have never seen a solution for quickly diagnosing time-critical diseases like Nexsen's suite of point-of-care diagnostics. The diagnostics appear to be a breakthrough with tremendous opportunity for international adoption and real-world clinical impact.

This global perspective is particularly relevant as health systems increasingly prioritise faster, decentralised diagnostics to reduce patient delays, improve triage efficiency and manage rising chronic disease burdens.

I am particularly excited about Nexsen's emerging suite of Kidney Function Tests for the early detection of Acute Kidney Injury and for monitoring renal dysfunction at home using laboratory-grade point-of-care tests. The ability to move beyond delayed, creatinine-based detection towards sensitive, actionable biomarkers has the potential to transform kidney care, prevent avoidable harm, and meaningfully improve patients' quality of life.

These biomarkers represent a significant advancement in early detection, with the potential to become the standard-of-care pathways in emergency, renal and primary-care settings.

What motivates me most is that Nexsen's platform is being designed to make sophisticated biomarker testing simple, rapid and truly point-of-care. By enabling easy testing of biomarkers that need timely bedside or home-based detection, this technology can empower clinicians with faster, more confident decision-making and support patients and families in managing complex conditions outside of hospital.

I am very pleased to join Nexsen at this pivotal stage and look forward to supporting the team as it advances from clinical validation to global commercial rollout."

Nexsen's Managing Director, Mark Muzzin, commented:

"Professor Kumta's appointment provides Nexsen with world-class clinical leadership and direct access to international healthcare networks. His experience aligns perfectly with our regulatory and revenues roadmap for our kidney diagnostics platform and supports our transition from clinical validation to commercial execution and partnership engagement.

We are pleased to welcome him at a time when the Company is building significant momentum toward global market entry, including preparation for US FDA 510(k) submission, international regulatory pathways and scaled manufacturing."

Nexsen's Chair, Reece O'Connell, commented:

"We are delighted to welcome Professor Kumta to the Board. His extensive international influence and experience integrating medical technologies into clinical practice significantly enhance Nexsen's capability to scale globally.

His contribution will be instrumental as we advance toward key regulatory, clinical and commercial milestones and progress toward key regulatory and market-access milestones.

His appointment further strengthens the Board as Nexsen prepares for a phase of accelerated growth, international expansion and sustained shareholder value generation."

Strengthening Global Market Access and Adoption Pathways.

Professor Kumta brings a distinctive combination of clinical influence, institutional access, and international experience that directly supports Nexsen's global market strategy. His background provides high-value entry points into two of the world's most established and strategically important healthcare systems, underpinned by deep practical experience in clinical adoption and change management.

- Extensive relationships across Hong Kong's public and private hospital networks, a critical regional gateway for the early adoption of maternal health diagnostics and an important market for point-of-care.
- Longstanding academic and clinical ties with NHS-linked institutions and clinicians in the United Kingdom, one of the most influential healthcare ecosystems globally for clinical guidelines, health technology assessment, and procurement decisions.
- Significant experience introducing new medical technologies into hospital workflows, clinical pathways, medical training environments, and translational research programs, ensuring that innovations are designed and validated for real-world adoption, reimbursement readiness and long-term clinical integration.

Together, these capabilities enable Nexsen to engage with health administrators, maternity services, renal specialists, procurement groups, and regulatory bodies across multiple jurisdictions earlier and more effectively. This enhances Nexsen's ability to accelerate efficient market access for the Company's diagnostic platform.

Addressing the Global Diagnostics Gap:

Across maternal health, emergency medicine, and chronic disease management, clinicians frequently lack tools that are both fast and accurate. Delayed diagnosis increases risk for mothers, newborns, and kidney-care patients, while placing preventable pressure on healthcare systems and driving significant cost inefficiencies.

This diagnostic gap represents a multibillion-dollar market opportunity across maternal health and renal medicine, where faster, decentralised systems increasingly prioritise decentralised testing.

Nexsen's platform aims to close this gap by enabling real-time, lab-quality diagnostic decisions at the bedside, shifting care from reactive to proactive and improving outcomes for millions of patients globally.

Next steps & Newsflow:

- Clinical trial progress for the GBS Rapid Test, including recruitment updates, interim findings and validation outcomes, supporting regulatory submissions and commercial readiness
- Preparation for U.S FDA 510(k) pathway engagement, including pre-submission planning and data-package preparation
- Development milestones across the Kidney Function Diagnostics suite
- Regulatory advancement, including continued preparation for U.S FDA engagement and assessments in international markets
- Updates on early commercial discussions, clinical partnerships and prospective evaluation sites across key markets
- Onboarding of early adopter hospital and commencement of real-world evidence programs
- Manufacturing and operational scale-up progress align with the anticipated market launch
- Further Advisory Board enhancements to support the Company's global commercial and clinical growth strategy

-ENDS-

ASX release authorised by the Board of Directors.

For more information, please contact:

Corporate Enquiries

Nexsen Limited

e: corporate@nexsen.bio

w: nexsen.bio

Reign Advisory

e: NXN@reignadvisory.com

p: + 61 2 9174 5388

Media Enquiries

Jane Morgan Management

e: info@janemorganmanagement.com.au

Join our Investor Centre

SCAN ME



About Nexsen Limited (ASX: NXN)

Nexsen is developing a suite of rapid point-of-care diagnostics that deliver lab-grade results for conditions that have traditionally relied on delayed lab testing. The company focuses on areas of significant unmet clinical need, where faster answers can improve patient outcomes and reduce pressure on healthcare systems.

Nexsen's lead diagnostic is the GBS Rapid Sensor, a rapid point-of-care diagnostic for detecting Group B Streptococcus, addressing a critical unmet need in maternal health. The company is also developing rapid kidney function tests for Acute Kidney Injury and Chronic Kidney Disease, two conditions that affect more than 850 million people globally and remain underserved by slow, lab-based diagnostics.

With further diagnostics in development across human health, ag-tech and biosecurity, Nexsen aims to become a global leader in rapid point-of-care diagnostics, delivering on its mission to ensure every person benefits from a Nexsen test at some point in their life.

Forward Looking Statements Disclaimer

Forward looking statements are typically identified by the use of forward looking terminology such as 'aims', 'believes', 'expects', 'may', 'will', 'could', 'should', 'seeks', 'intends', 'estimates', 'plans', 'assumes', 'envisages', or the negative thereof or other words of similar meaning. Examples of such forward looking statements include, among others, statements or discussions regarding the Company's business, financial or investment strategies, regulatory and product rollout strategies, estimates of expenditure, present or future plans or events, prospects, growth, objectives for future operations and estimates. Such forward looking statements include matters that are not historical facts and are subject to a number of risks and uncertainties, many of which are beyond the Company's control and all of which are based on the Company's current beliefs, intentions or expectations about future events. Such statements are, by their nature, subject to a number of known and unknown risks, uncertainties, assumptions and other important factors that could cause actual results, performance or achievements to differ materially from any expected future results, performance or achievements expressed or implied, by the forward looking statement.

Neither the Company nor any person gives any representation, assurance or guarantee that the occurrence of the event expressed or implied in any forward looking statements in this document will actually occur and you are cautioned not to place undue reliance on such forward looking statements. Factors that might cause forward looking statements to differ materially from actual results, performance or achievements include, among other things, global economic conditions, economic conditions in jurisdictions in which the Company may operate or invest, credit markets, legislative fiscal and regulatory developments, the effects of continued volatility in markets and exchange rate fluctuations. The forward looking statements contained in this document speak only as of the date this document and each of the Company, respective directors, officers, employees, agents, representatives and/or advisers expressly disclaims any obligations or undertaking to release any update of, or revisions to, any forward looking statements in this document.